OpenRounds Editorial
Daily Briefing
Thursday, May 21, 2026
What Changed
Inside the 'glass box': Why one physician thinks AI in medicine must show its work (Healthcare IT News) sets the agenda today, with TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15 (Proceedings of the National Academy of Sciences of the United States of America) reinforcing the same shift toward decisions healthcare AI leaders may need to track now [1][2].
Research
•[AI Evidence] TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15 (Proceedings of the National Academy of Sciences of the United States of America) [2]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
Policy & Ops
•[AI in Clinical Operations] Inside the 'glass box': Why one physician thinks AI in medicine must show its work (Healthcare IT News) [1]. It has nearer-term implications for implementation planning, reimbursement exposure, staffing, or clinical workflow governance. Local execution details, workflow fit, and follow-through will matter more than the headline alone.
•[AI in Clinical Policy] Senate Democrats move to roll back Medicare AI prior authorization pilot (Healthcare Dive) [3]. It has nearer-term implications for implementation planning, reimbursement exposure, staffing, or clinical workflow governance. Local execution details, workflow fit, and follow-through will matter more than the headline alone.
•[AI in Clinical Policy] How AI & CMS are Solving the $4 Trillion Healthcare Crisis (MedCity News) [4]. It has nearer-term implications for implementation planning, reimbursement exposure, staffing, or clinical workflow governance. Local execution details, workflow fit, and follow-through will matter more than the headline alone.
•[AI in Clinical Operations] Development, Feasibility, Acceptability, and Usability of an Artificial Intelligence-Powered Chatbot (Suzy) to Support Patients in Substance Use Disorder Recovery: Multiphase Study (JMIR formative research) [5]. It has nearer-term implications for implementation planning, reimbursement exposure, staffing, or clinical workflow governance. Local execution details, workflow fit, and follow-through will matter more than the headline alone.
Industry & Products
•[AI in Biopharma] Anthropic signs enterprise AI deal with Bristol Myers Squibb (MobiHealthNews) [6]. It is a clearer market signal for buyers and investors tracking where healthcare AI budgets and enterprise priorities may move next. Company momentum and launches are not the same thing as scaled health-system adoption or clinical outcomes.